Biotech Isis Pharmaceuticals (ISIS) saw its shares rise Thursday after the company reported positive midstage data on a rare-disease drug candidate. Its development partner Biogen (BIIB) also got a lift. Isis stock was up 3% in midday trading in the stock market today, near 68.50. Earlier, Isis stock rose as high a 71.50, to a nearly three-month high. Biogen stock was up 1.5% in midday trading Thursday. Isis reported on a phase-two trial of
IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all
After reporting mixed quarterly results, top-rated biotech Celgene (CELG) looks to have unraveled its base-building effort. The stock dropped 5% on the stock market today, falling to a four-month low. Celgene’s earnings grew 27% and beat estimates by a penny. Sales increased 20% but missed views. Group peer Biogen (BIIB) has yet to retake its 50-day line after it gapped below that area when Q1 results missed estimates last Friday. Will fellow